Leadership Team
-
Anya Ragnhildstveit
Chief Executive Officer
Anya is a clinical research scientist with expertise in child, adolescent, and adult psychiatry. Her work focuses on the safety and therapeutic potential of ketamine, MDMA, and classic psychedelics for treating eating disorders, PTSD, and suicidality.
Full Biography ↗
-
Paul Seli, PhD
Chief Scientific Officer
Paul is a Harvard-trained cognitive psychologist and IFS practitioner with expertise in mind wandering, creativity, and mental health. His work examines the cognitive, social, and clinical effects of psychedelics in experimental and naturalistic settings.
Full Biography ↗
-
Jamarie Geller, MD
Chief Clinical Officer
Jamo is a board-certified psychiatrist, contemplative psychotherapist, and adjunct clinical assistant professor of psychiatry. Her work focuses on ketamine- and psychedelic-assisted psychotherapy for child, adolescent, and adult mental health.
Full Biography ↗
-
Rachel Pacilio, MD
Chief Medical Officer
Rachel is a board-certified psychiatrist and clinical assistant professor of psychiatry with expertise in pediatric and perinatal mental health. Her work explores female-specific applications of psychedelics, such as for eating disorders and postpartum depression.
Full Biography ↗
-
Miriam Kaiyo, PhD
Chief Impact Officer
Miriam is a trauma‑informed psychedelic facilitator and human development specialist. Her work centers on ethical, inclusive, and community‑based healing practices that foster spirituality, mental health, and social well-being across the lifespan.
Full Biography ↗
-
Jonathan Schooler, PhD
Chief Scientific Advisor
Jonathan is a cognitive scientist and distinguished professor of psychological and brain sciences. His work focuses on the nature of mental life, specifically consciousness, and the effects of psychedelics on subjectivity, brain function, and behavior.
Full Biography ↗
-
Reid Robison, MD, MBA
Chief Medical Advisor
Reid is a board-certified psychiatrist, IFS therapist, and adjunct professor of psychiatry with expertise in eating disorders. He has led over 250 clinical trials to date, including pivotal Phase 2 and 3 psychedelic studies sponsored by MAPS, Cybin, and MindMed.
Full Biography ↗
-
Nathaniel Barr, PhD
Chief Innovation Advisor
Nate is a cognitive psychologist and professor of creativity and creative thinking. His work examines human nature and mind-manifesting experiences that enable collective transformation through the lenses of psychology, behavior change, and creativity.
Full Biography ↗